Improved prognosis of patients with intermediate-and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment

BJU International

Volumn 92, Issue 1, 2003, Pages 36-42

  Pentheroudakis, G ^a,c   De Bono, J S ^a   Kaye, S B ^a   Simpson, A ^a   Paul, J ^a   Brown, I ^b   Pamenter, B ^b   Kirk, A ^b   Vasey, P ^a   Raby, N ^b   Kirk, D ^b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Chemotherapy; Germ cell cancer; Poor risk; Surgery

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PLATINUM; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; MALE; METASTASIS; MORBIDITY; MULTIMODALITY CANCER THERAPY; NON SEMINOMATOUS GERMINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 0038502398     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04261.x     Document Type: Article

References (23)

1. Schmoll HJ. Treatment of testicular tumours based on risk factors. Curr Opin Urol 1999; 9: 431-8
2. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603
3. Sonneveld DJ, Hoekstra HJ, van der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-15
4. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic non-seminomatous germ cell tumour: a randomised Medical Research Council/European Organisation for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701
5. De Bono JS, Paul J, Simpson A et al. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours. Br J Cancer 2000; 83: 426-30
6. Collette L, Sylvester RJ, Stenning SP et al. Impact of the treating institution on survival of patients with poor prognosis metastatic non seminomatous germ cell tumours. J Natl Cancer Inst 1999; 91: 839-46
7. Anthoney DA, Roberts J, Graham J, Mckean MJ, Paul J, Kaye SB. Alternating bleomycin, vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP) chemotherapy as a dose intense regimen for intermediate and poor prognosis malignant germ cell tumours (MGCT). Proc Am Soc Clin Oncol 1999: 214P
8. Cassidy J, Lewis CR, Kaye SB, Kirk D. The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer 1992; 65: 127
9. Steyerberg EW, Donohue JP, Gerl A et al. Residual masses after chemotherapy for metastatic testicular cancer. the clinical implications of the association between retroperitoneal and pulmonary histology. J Urol 1997; 158: 474-8
10. Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8: 477-83
11. Hendry WF, A'Hern RP, Hetherington JW et al. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours. prognostic value and therapeutic benefit. Br J Urol 1993; 71: 208-13
12. Fossa SD, Stenning S, Gerl A et al. Prognostic factors in patients with malignant non-seminomatous germ cell tumours relapsing after cisplatin based chemotherapy. Br J Cancer 1999; 80: 1392-9
13. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours. prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001; 19: 2647-57
14. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in post-chemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41
15. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumour. differentiation of viable tumour, mature teratoma, and necrotic tissue with FDG PET kinetic modeling. Radiology 1999; 211: 249-56
16. Izquierdo MA, Van der Valk P, Van Ark-Otte J et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 1995; 177: 253-8
17. Ravi R, Ong J, Oliver RTD, Badenoch DF, Fowler CG, Hendry WF. Surgery as salvage in chemotherapy-resistant non-seminomatous germ-cell tumours. Br J Urol 1998; 81 (Suppl. 4): 5
18. Nichols C, Maziarz R. High dose chemotherapy - results of American studies. Int J Cancer 1999; 83: 841-3
19. Domer PH, Head DR, Renganathan N et al. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995; 9: 1305-12
20. Perttunen K, Tasmuth T, Kelso E. Chronic pain after thoracic surgery: a follow-up study. Acta Anaesthesiol Scand 1999; 5: 563-7
21. Baniel J, Foster R, Rowland R, Donohue J. Complications of primary retroperitoneal lymph node dissection. J Urol 1994; 152: 424
22. Wood DP, Herr HW, Heller G et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumours. J Urol 1992; 148: 1812-5
23. Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses. Is a modified dissection and resection of residual masses sufficient? Br J Urol 1998; 81: 295-300